Tissue Regenix confident on post-COVID-19 prospects
The capacity expansion programme will alleviate the supply issues that have previously hindered growth and will provide a step-change in the business trajectory, the firm said
Tissue Regenix Group PLC (LON:TRX) said it is confident in its prospects once the Coronavirus (COVID-19) pandemic subsides and healthcare procedures return to a normalised level.
The medical technology company has entered the UK and specific EU markets with OrthoPure XT and established white label manufacturing capabilities with a large global partner.
The capacity expansion programme will alleviate the supply issues that have previously hindered growth and will provide a step-change in the business trajectory, as the firm secures additional distribution contracts and increases its geographic outreach.